Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa
contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin.
In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to
receive Colistin alone and another group will receive Colistin plus Rifampicin.